Advertisement

Induction of Graft-versus-Leukemia-Activity after Peripheral Blood Progenitor Cell Transplantation (PBPCT)

  • L. Uharek
  • B. Glass
  • M. Zeis
  • J. P. Dreger
  • J. Steinmann
  • N. Schmitz
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 39)

Abstract

Using a murine transplantation model we have investigated the induction of GvL activity with allogeneic peripheral blood progenitor cells (PBPCs). We compared the influence of allogeneic PBPC and BM grafts on GvHR and leukemic relapse in mice bearing a B-lymphoblastic leukemia (A20). Furthermore, we evaluated the impact of T cell depletion on the risk of relapse and determined the effectiveness of ex vivo treatment with NK-cell activating cytokines as a compensation for the loss of T-cell derived factors stimulating natural cytotoxicity. Methods: After pretreatment of Balb/c (H-2d) recipients with 7.5 Gy of total body irradiation, 2 × 107 rhG-CSF-mobilized PBPCs of syngeneic or MHC-identical DBA (H-2d) mice were transfered. Selective T-cell depletion (TCD) was performed by immunomagnetic purging with a monoclonal antibody directed against CD3. In some ex-perimental groups, T-cell-depleted PBPCs were incubated with 200 U/ml IL-2 and 100 U/ml IL-12 for 24 hrs. To investigate anti-leukemic activity in vivo, recipient mice were inoculated with 1 × 105A-20 cells (a Blymphoblastic leukemia of Balb/c origin) 2 days prior to PBPCT. Results: The mortality rate due to GVHD was identical after allogeneic BMT and allogeneic PBPCT, although PBPC grafts contained the fourfold amount of CD3+ T cells than BMC grafts (61% vs. 15%). The relapse rates were 80% after syngeneic PBPCT and 60% after allogeneic BMT. After allogeneic PBPCT, a relapse rate of 34% was observed, indicating significantly (p < 0.05)superior GVL activity of PBPCT. After TCD of allogeneic grafts with antiCD3, the incidence of GvH-related mortality was below 5% but leukemia free survival was decreased to 25% and thus was similar to syngeneic PBPCT (17%, p < 0.05). When CD3-depleted grafts were incubated with IL-2 and IL-12, 45% of the animals remained free from leukemia. However, the difference was statistcally not significant. Our results suggest that stronger GVL effects can be induced by transplantation of PBPC as compared to BM grafts and that the ex-vivo activation of residual MHC-matched NK-cells with IL-2 and IL-12 does not fully compen-sate for the abrogation of GvL-activity after depletion of CD3-positive T-cells.

Keywords

Peripheral Blood Progenitor Cell Antileukemic Activity Bone Marrow Graft Leukemia Free Survival Allogeneic Peripheral Blood Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringdén O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555PubMedGoogle Scholar
  2. 2.
    Antin JH (1993) Graft-versus-leukemia effect: no longer an epiphenomenon. Blood 82: 2273PubMedGoogle Scholar
  3. 3.
    Weiden PL, Flournoy MS, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 300: 1068–1073PubMedCrossRefGoogle Scholar
  4. 4.
    Glass B, Uharek L, Gassmann W, Focks, B, Bolouri, H, Loeffler H, Mueller-Ruchholtz W (1992) Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease. Ann Hematol 64: 255–259PubMedCrossRefGoogle Scholar
  5. 5.
    Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loftier H, Hunter A, Russell NH (1995) Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85: 1666PubMedGoogle Scholar
  6. 6.
    Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD (1995) Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85: 1655PubMedGoogle Scholar
  7. 7.
    Dreger P, Viehmann K, Steinmann J, Eckstein V, Muller-Ruchholtz WH, Schmitz N (1995) GCSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. Experimental Hematology 23: 147PubMedGoogle Scholar
  8. 8.
    Schmitz N, Bacigalupo A, Labopin M, Majolino I, Laporte JP, Brinch L, Cook G, Lambertenghi Deliliers G, Lange A, Rozman C, Garcia-Conde J, Finke J, Domingo-Albos A, Gratwohl A (1996) Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. Br J Haematol 95: 715PubMedCrossRefGoogle Scholar
  9. 9.
    Bensinger WI, Weaver CH,Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD (1995) Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85: 1655PubMedGoogle Scholar
  10. 10.
    Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JLL, Michallet M, Dreyfus F, Ifrah N (1987) Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 2: 175PubMedCrossRefGoogle Scholar
  11. 11.
    Uharek L, Gassmann W, Glass B, Steinmann J, Loeffler, H (1992) Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 79: 1612PubMedGoogle Scholar
  12. 12.
    Uharek L, Glass B, Gaska T, Gassmann W, Loeffler H, Mueller-Ruchholtz W (1994) Influence of donor lymphocytes on the incidence of primary graft failure after allogeneic bone marrow transplantation in a murine model. British Journal of Haematology 88: 79PubMedCrossRefGoogle Scholar
  13. 13.
    Horowitz MM, Messerer D, Hoelzer D, Gale RP, Neiss A, Atkinson KB, Buchner T, Freund M, Heil G (1991) Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Annals of Internal Medicine 115: 13PubMedGoogle Scholar
  14. 14.
    Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham ICH, O’Reilly RJ, Keever CA (1990) Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 75: 2250PubMedGoogle Scholar
  15. 15.
    Glass B, Uharek L, Zeis M, Loeffler H, Mueller Ruchholtz W, Gassmann W (1996) Graft-versusleukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol 93: 412PubMedCrossRefGoogle Scholar
  16. 16.
    Vallera DA, Soderling CCB, Carlson GJ, Kersey JH (1981) Bone marrow transplantation across major histocompatibility barriers in mice. Effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement or antibody alone. Transplantation 31: 218PubMedCrossRefGoogle Scholar
  17. 17.
    Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni CIR, Zei T, Martelli MP, Gambe-lunghe C (1994) Successful engraftment of Tcell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84: 3948PubMedGoogle Scholar
  18. 18.
    Zeis M, Uharek L, Glass B, Gaska T, Steinmann J, Gassmann W, Loffler H, Muller-Ruchholtz W (1995) Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 59: 1734PubMedCrossRefGoogle Scholar
  19. 19.
    Zeis M, Uharek L, Glass B, Gaska T, Gassmann W, Mueller-Ruchholtz W (1994) Induction of graftversus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts. Bone Marrow Transplantation 14: 711PubMedGoogle Scholar
  20. 20.
    Moretta L, Ciccone E, Mingari MC, Biassoni R, Moretta A (1994) Human natural killer cells: origin, clonality, specificity, and receptors. Advances in Immunology 55: 341PubMedCrossRefGoogle Scholar
  21. 21.
    Champlin R, Pasweg J, Horowitz M, and for the International Bone Marrow Transplant Registry (1995) Blood T-cell Depleted (TCD) BMT for Leukemia Patients with Donors Other than HLA-identical Siblings ( Abstract ). Blood 86: 94aGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • L. Uharek
    • 1
  • B. Glass
    • 1
  • M. Zeis
    • 1
  • J. P. Dreger
    • 1
  • J. Steinmann
    • 2
  • N. Schmitz
    • 1
  1. 1.Department of Internal Medicine IIGermany
  2. 2.Institute of ImmunologyUniversity of KielGermany

Personalised recommendations